In a patient with a homozygous MTHFR C677T mutation and elevated homocysteine, should I use folic acid, folinic acid (leucovorin), or 5‑methyltetrahydrofolate (5‑MTHF) as supplementation?

Use 5-Methyltetrahydrofolate (5-MTHF) for Homozygous MTHFR C677T Mutation with Elevated Homocysteine

In a patient with homozygous MTHFR C677T mutation and elevated homocysteine, you should prescribe 5-methyltetrahydrofolate (5-MTHF), not folic acid or folinic acid. This recommendation is based on the biochemical reality that the MTHFR enzyme deficiency in TT homozygotes impairs conversion of folic acid to its active form, making 5-MTHF the logical choice since it bypasses the defective enzyme entirely 1.

Why 5-MTHF is Superior for MTHFR 677TT Genotype

The homozygous MTHFR C677T mutation creates a thermolabile enzyme with reduced activity, directly impairing the conversion of folic acid to 5-methyltetrahydrofolate. 5-MTHF does not require any conversion by MTHFR 1, making it immediately bioavailable for homocysteine remethylation to methionine. This is the critical mechanistic advantage.

European Heart Journal guidelines explicitly state: "In the case of increased Hcy levels due to the presence of MTHFR 677TT genotype, then oral 5-MTHF treatment should be considered, since this agent does not require any conversion by MTHFR" 1.

Evidence Supporting 5-MTHF Efficacy

• Homocysteine reduction: 5-MTHF reduces homocysteine comparably to folic acid in both wild-type and TT homozygotes, with reductions from 16.9 ± 6.8 to 11.6 ± 4.4 μmol/L after 7 weeks 2
• Sustained effect: A unique finding showed that 6 months after stopping 5-MTHF treatment, homocysteine levels remained significantly lower than baseline only in TT homozygotes (12.1 vs 16.9 μmol/L, P < 0.01), suggesting a prolonged phenotypic benefit 2
• Superior pharmacokinetics: 5-MTHF achieves higher plasma concentrations (AUC and Cmax) and faster absorption (shorter tmax) compared to folic acid, regardless of MTHFR genotype 3

Why NOT Folic Acid

Folic acid requires reduction by dihydrofolate reductase (DHFR) and then conversion by MTHFR to become 5-MTHF. In TT homozygotes, this pathway is compromised. Additionally:

• Unmetabolized folic acid accumulation: High-dose folic acid increases circulating but not intracellular 5-MTHF 1, potentially masking B12 deficiency
• DHFR polymorphism interaction: A common 19-base pair deletion in DHFR further impedes folic acid conversion, present in 29.5% as homozygous deletion 4
• Reduced efficacy in TT genotype: While folic acid works, it's biochemically illogical when the active form is available

What About Folinic Acid (Leucovorin)?

Folinic acid (leucovorin) is 5-formyltetrahydrofolate, which is rapidly metabolized to 5-methyltetrahydrofolate 5. While it bypasses DHFR, it still requires enzymatic conversion to reach the active 5-MTHF form.

Recent research comparing folinic acid to 5-MTHF showed:

• Both reduced homocysteine effectively in healthy adults 6
• Folinic acid caused higher serum folate levels but no difference in homocysteine reduction compared to 5-MTHF 6
• Individuals with MTHFR 677CT (heterozygous) had greater homocysteine reduction with folinic acid, but this doesn't apply to your TT homozygous patient 6

Folinic acid's primary indication is as a rescue agent for methotrexate toxicity 5, not as first-line folate supplementation for MTHFR mutations.

Practical Prescribing Algorithm

For MTHFR 677TT with elevated homocysteine:

1. Prescribe 5-MTHF: 400-800 μg daily (some practitioners use up to 2000+ μg based on homocysteine levels 7)
2. Add methylcobalamin or hydroxycobalamin: 0.02-1 mg daily, as B12 is a cofactor for methionine synthase 4, 1
3. Consider vitamin B6: 50-250 mg daily if homocysteine remains elevated, as it's a cofactor for cystathionine-β-synthase 1
4. Monitor homocysteine: Recheck at 3 months; expect 25-30% reduction 1

Important Caveats

• Stroke prevention context: The 2022 Stroke guideline suggests TT homozygotes with both folate and B12 above median actually respond better to treatment (HR 0.28) 4, emphasizing the importance of adequate B12 co-supplementation
• Avoid intramuscular B12 unless deficient: Only use if serum cobalamin <300 pg/mL 6
• Don't use leucovorin routinely: Reserve for chemotherapy rescue; it's not the optimal form for MTHFR mutations despite bypassing DHFR

The Bottom Line

5-MTHF is the biochemically rational choice for homozygous MTHFR C677T mutations because it's the end product of the defective enzymatic pathway. While folic acid and folinic acid can work through alternative mechanisms, using 5-MTHF eliminates the metabolic bottleneck entirely and provides the active folate form directly for homocysteine remethylation. Combine with methylcobalamin for optimal homocysteine reduction and potential cardiovascular risk reduction.